^
    Back
    Association details:
    Biomarker:BCL2 expression + MYC expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Epidaza (chidamide) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    PRNewswire
    Title:

    National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

    Published date:
    04/30/2024
    Excerpt:
    Shenzhen Chipscreen Biosciences Co...announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), has been officially approved by the National Medical Products Administration (NMPA) for treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) with positive MYC and BCL2 expression.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    1197 Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study

    Published date:
    11/04/2020
    Excerpt:
    An open-label, multicenter, phase 2 study (NCT04022005) was initiated to evaluate the efficacy and safety of chidamide plus R-GemOx(CR-GemOx)...Notably, 2 CR and 2 PR were reported in 6 pts with BCL-2/MYC double-expression (DE). With a median follow-up of 8.4 months, the median PFS was 7.4 months…
    Trial ID:
    NCT04022005